Health Care Equipment

EDAP TMS

EDAP TMS released FY2026 Q1 earnings on May 7 Pre-Market EST, actual revenue USD 17.81 M (forecast USD 16.6 M), actual EPS USD -0.2423 (forecast USD -0.25)

EDAP TMS Releases Breakthrough Study on Focal One Robot for Prostate Cancer Treatment

EDAP TMS to Release FY2026 Q1 Earnings on May 7, Pre-Market EST; Forecast Revenue USD 16.6 M, EPS USD -0.2333

EDAP TMS released FY2025 earnings on March 25 Pre-Market (EST), actual revenue USD 71.92 M (forecast USD 70.55 M), actual EPS USD -0.7965 (forecast USD -0.6793)

EDAP TMS released FY2025 Q4 earnings on March 25 Pre-Market (EST), actual revenue USD 19.48 M (forecast USD 21.28 M), actual EPS USD -0.2259 (forecast USD -0.148)

EDAP TMS to release FY2025 Q4 earnings on March 25 Pre-Market EST, forecast revenue USD 21.28 M, EPS USD -0.148

EDAP TMS released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 16.28 M (forecast USD 15.12 M), actual EPS USD -0.157 (forecast USD -0.251)

EDAP TMS released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 49.73 M and EPS of USD -0.537

EDAP TMS to release FY2025 Q3 earnings on November 6, Pre-Market EST, with forecast revenue of USD 15.05 M and EPS of USD -0.251

EDAP TMS released FY2025 Semi-Annual Earnings on August 28 Pre-Market (EST), Actual Revenue: USD 33.35 M, Actual EPS: USD -0.3816

EDAP TMS released FY2025 Q2 earnings on August 28 Pre-Market (EST), actual revenue USD 18.78 M (forecast USD 16.6 M), actual EPS USD -0.1751 (forecast USD -0.1793)

EDAP TMS SA Receives EIB Credit Line to Support Focal One® Growth

EDAP TMS to Release FY2025 Q2 Earnings on August 28 Pre-Market EST, Forecast Revenue USD 16.6 M, EPS USD -0.1793

Edap TMS SA to Report 2025 Second Quarter Earnings

EDAP TMS SA no longer meets foreign private issuer status

EDAP TMS released FY2025 Q1 earnings on May 15 Pre-Market (EST), actual revenue USD 14.68 M (forecast USD 16.56 M), actual EPS USD -0.2047 (forecast USD -0.1643)

Edap TMS SA Reports 9.1% Revenue Drop in Q1 2025

Multiple Analysts Evaluate Edap Tms Ratings and Price Targets

EDAP TMS to release FY2025 Q1 earnings on May 15, pre-market EST, forecast revenue USD 16.56 M, EPS USD -0.1643

EDAP TMS SA Announces Positive Results for Prostate Treatment Study

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News

StockTitan

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News

AKTX

EDAP

EVAX

MREO

European equities traded in the US as American depositary receipts saw a slight increase of 0.08% to 1,829.64 on the S&P Europe Select ADR Index. Notable gainers included Nokia (up 4.1%) and Evaxion (up 3.9%), while SAP and EDAP TMS led the decliners with drops of 4.8% and 4.7%, respectively. In the UK, Akari Therapeutics rose 11%, while Mereo BioPharma Group fell 3.1%.

Fidelity

Akari Therap

Nokia Oyj

Evaxion A/S

Mereo Biopharma

SAP SE

Ascendis Pharmac

Trivago NV

SAP AG-Sponsored

DBV Tech

Natuzzi SPA

Autolus Therapeutics

 BHP Group Ltd

Vodafone 

Vodafone Group Plc

Endava

Biodexa Pharmaceuticals

Pearson

Pearson PLC

BHP Group Limited

BHP Group Plc

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

Earnings Watch

EDAP TMS | 10-Q: FY2026 Q1 Revenue: USD 17.81 M

EDAP shares are trading higher after the company reported better-than-expected Q1 sales results.

benzinga_article

BDRX

01876

HSBA

HSBC

European equities traded in the US as American depositary receipts rose 0.27% to 1,794.86 on the S&P Europe Select ADR Index. Notable gainers included Anheuser-Busch InBev (up 9%) and EDAP TMS (up 3%). Decliners included Sequans Communications (down 9.7%) and Criteo (down 3.9%). In the UK, Biodexa Pharmaceuticals surged 32%, while HSBC fell 5%.

BUD APAC

HSBC Holdings Plc

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

On April 30, 2026, medical technology company EDAP TMS announced significant progress in enhancing their market presence. They released groundbreaking results from the HIFI-2 study, which provided strong support for the effectiveness of their Focal One ® Robotic HIFU system in treating radiorecurrent prostate cancer. This data is expected to solidify EDAP TMS's position in the market as a leader in innovative medical solutions.

Unusual Whales

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer

CLLS

DAVA

European equities traded in the US as American depositary receipts fell 0.45% to 1,779.46 on the S&P Europe Select ADR Index. Notable gainers included Nokia (up 6.1%) and EDAP (up 3.8%), while Cellectis and Royal Philips led the decliners, falling 6.1% and 5.6%, respectively. In the UK, WPP and Endava saw gains of 2.7% and 1.2%, while Akari Therapeutics and GSK dropped 8% and 7%.

Cellectis

Koninklijke Philips Elect

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

Edap Tms S.A. (NASDAQ:EDAP) experienced a significant decrease in short interest, dropping 32.3% to 37,921 shares as of April 15. The short-interest ratio is currently 1.5 days, with 0.1% of shares sold short. Analysts have mixed ratings on the stock, with one Buy, two Hold, and one Sell. The average price target is $6.00. Institutional investors hold 62.74% of the company. EDAP stock is trading at $3.28, with a market cap of $122.94 million. The company reported a loss of $0.25 EPS for the last quarter, missing estimates.

Market Beat

Edap Tms S.A. (NASDAQ:EDAP) Short Interest Update

EDAP TMS(EDAP.US)

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

EDAP TMS | 10-Q: FY2026 Q1 Revenue: USD 17.81 M

EDAP shares are trading higher after the company reported better-than-expected Q1 sales results.

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

Edap Tms S.A. (NASDAQ:EDAP) Short Interest Update